Recently, NATURE published the latest results based on whole-genome, whole-transcriptome and DNA methylation data, revealing the genomic changes in Chinese patients were markedly different from those in Western patients (41% FOXA1 mutation in PCa as the most prominent signature in the Chinese population), and emphasized the importance of individualized treatment based on ethnic genetic background [18]. The gene discussed is FOXA1; the disease is posterior cortical atrophy.